The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

Andrea Botticelli; Agnese Fabbri; Michela Roberto; Daniele Alesini; Alessio Cirillo; Giuliana D'Auria; Eriseld Krasniqi; Eleonora Marrucci; Margherita Muratore; Francesco Pantano; Laura Pizzuti; Ilaria Portarena; Rosalina Rossi; Simone Scagnoli; Paolo Marchetti

doi:10.3389/fonc.2022.797157

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

Front Oncol. 2022 Feb 9:12:797157. doi: 10.3389/fonc.2022.797157. eCollection 2022.

Authors

Andrea Botticelli^{1

2}, Agnese Fabbri³, Michela Roberto^{2

4}, Daniele Alesini⁵, Alessio Cirillo^{1

6}, Giuliana D'Auria⁷, Eriseld Krasniqi⁸, Eleonora Marrucci³, Margherita Muratore⁹, Francesco Pantano¹⁰, Laura Pizzuti⁸, Ilaria Portarena¹¹, Rosalina Rossi¹², Simone Scagnoli^{1

13}, Paolo Marchetti^{1

2}

Affiliations

¹ Medical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
² Department of Clinical and Molecular Medicine, Sapienza University of Rome, Oncology Unit, Sant'Andrea Hospital, Rome, Italy.
³ Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
⁴ Medical Oncology Unit A, Policlinico Umberto I, Rome, Italy.
⁵ UOSD Centro Oncologico S. Spirito e Nuovo Regina Margherita (SS-NRM), Ospedale Santo Spirito in Sassia, Rome, Italy.
⁶ Department of Radiological, Oncological and Anatomo-Pathological Science, "Sapienza" University of Rome, Rome, Italy.
⁷ Department of Medical Oncology, Sandro Pertini Hospital, Rome, Italy.
⁸ Division of Medical Oncology 2, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.
⁹ Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Roma, Italy.
¹⁰ Department of Oncology, University Campus Biomedico of Rome, Rome, Italy.
¹¹ Medical Oncology Unit, Internal Medicine Department, Tor Vergata Clinical Center University Hospital, Rome, Italy.
¹² Medical Oncology, San Giovanni Addolorata Hospital, Rome, Italy.
¹³ Department of Medical and Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Rome, Italy.

Abstract

The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 -) advanced breast cancer (ABC). Ribociclib showed to be effective across most subgroups, regardless of the number and the site of metastasis. Up to 10% of patients with ABC, reported an oligometastatic condition, recently defined as a slow-volume metastatic disease with limited number and size of metastatic lesions (up to 5 and not necessarily in the same organ), potentially amenable for local treatment, aimed at achieving a complete remission status. Despite the wide use of CDK4/6 inhibitors in HR+, HER2-, ABC treatment, data regarding both locally advanced, inoperable disease and oligometastatic conditions are still poor. We reported a review and case series of HR+, HER2-, ABC patients treated with ribociclib as first-line therapy, for a locally advanced and oligometastatic conditions, reporting an impressive response and good safety profile.

Keywords: CDK4/6 inhibitor; case report; locally advanced breast cancer (LABC); oligometastatic; ribociclib.